Onconova Therapeutics Inc.

230 articles about Onconova Therapeutics Inc.

• Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor

  12/21/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced receipt of U.S. Food and Drug Administration (FDA) permission for a Phase 1 study to proceed under the Company’s Investigational New Drug application (IND) for ON 123300, a proprietary, differentiated, first-in-class multi-kinase inhibitor. “We are grateful to receive this timely, favora

• Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

  11/23/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the filing of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for ON 123300, the Company’s proprietary, differentiated, first-in-class multi-kinase inhibitor.

• Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/12/2020

  Onconova Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported financial results for the quarter ended September 30, 2020 and provided a business update.

• Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 12

  11/5/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company intends to release its third quarter financial results on Thursday, November 12, 2020 after market close. Management plans to host a conference call and live webcast at 4:30 p.m.

• Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event

  10/13/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1x1 meetings scheduled through t

• Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

  9/21/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the initiation of a Phase 1 clinical trial in China for ON 123300 by its partner, HanX Biopharmaceuticals.

• Onconova Therapeutics Announces Participation at Upcoming Virtual Events

  9/9/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company plans to participate in several upcoming events:

• 

  BioSpace Movers & Shakers, Sept. 4

  9/4/2020

  Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.

• Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors

  8/31/2020

  Onconova remains focused on development of its proprietary pipeline of targeted agents as it enters a new phase as a biopharmaceutical company

• Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial

  8/24/2020

  IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS) Onconova will focus on promising pipeline opportunities including with its CDK4/6 + ARK5 inhibitor ON 123300 Onconova to host conference call today at 8:30 a.m. ET NEWTOWN, Pa., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel produ

• Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results

  8/12/2020

  INSPIRE Phase 3 trial survival events reached Topline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today reported financial results for the quarter ended June 30, 2020, and pr

• Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12

  8/7/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the Company intends to release its second quarter financial results on Wednesday, August 12, 2020. Management plans to host a conference call and live webcast at 4:30 p.m. ET on that day to discuss these results and

• Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement

  8/4/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that on August 3, 2020 it received a letter from The Nasdaq Stock Market LLC stating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq Listing Rule 5550(a)(2) because the Compa

• Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data AnalysisTopline INSPIRE Results are Expected by the End of the Third Quarter of 2020

  7/29/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the required number of survival events for the pivotal Phase 3 INSPIRE has been reached.

• Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease

  7/27/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has submitted an application with the National Institute of Allergy and Infectious Disease (NIA

• Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy

  7/23/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the publication (Molecular Cell 79, 180-190, 2020) of in vitro data further supporting rigosertib’s role in modulating RAS cellular signaling. “We believe this data sheds light on the capacity of Onconova’s targeted an

• Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS

  7/7/2020

  RAS-focused mechanism of action and manageable side effect profile indicate potential promise for oral rigosertib as part of future combination therapies

• Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar

  6/23/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced its participation in the Noble Capital Markets c-suite webinar series. The webinar was led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D., with participation by Steven M. Fruchtman, M.D., President and

• Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma

  6/22/2020

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS) today announced an investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) lung adenocarcinoma has begun enrolling patients. “Over half of non-small cell lung cancers are cl

• Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)

  6/12/2020

  RAS Pathway Mutations Were Observed More Commonly in Patients That Progressed on HMA Therapy vs Patients That Failed HMA Therapy Completely